ASH 2019 | David Maloney’s ASH 2019 CAR-T highlights
David Maloney
• 7 Dec 2019
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, highlights the key updates in the CAR T-cell therapy field from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Dr Maloney specifically discusses the phase I study (NCT03338972) combining BCMA CAR T-cells with a small molecule gamma secretase inhibitor in multiple myeloma (MM). Additionally, Dr Maloney mentions a study of mosunetuzumab, a bispecific antibody, in lymphoma patients who have relapsed or are resistant to CAR-T therapy (GO29781; NCT02500407).
